William Guyer sold $490k of CORT
Chief Development Officer at CORCEPT THERAPEUTICS INC. 10,000 shares at an average of $48.97, traded Nov 1, 2024, filed Nov 5, 2024.
Score components
- +15RoleOfficer
- +18Trade size$490k at market
- +20Share of holdings soldSold 81% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +14.0%, 3m +28.3%, 6m +35.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-121742, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | MOption exercise Common Stock10b5-1 | +6,606 | $21.65 | $143k | 12,402 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Common Stock10b5-1 | -6,606 | $48.97 | $323k | 5,796 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Common Stock10b5-1 | +3,394 | $21.65 | $73k | 9,190 | Nov 5, 2024 |
| Nov 4, 2024 | SOpen-market sale Common Stock10b5-1 | -3,394 | $48.97 | $166k | 5,796 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Stock option (right to buy)derivative10b5-1 | -6,606 | $0.00 | $0 | 453,394 | Nov 5, 2024 |
| Nov 4, 2024 | MOption exercise Stock option (right to buy)derivative10b5-1 | -3,394 | $0.00 | $0 | 450,000 | Nov 5, 2024 |
Related signals
Other insiders at CORCEPT THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -242% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.2M 10,000 shares | -154% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $967k 8,333 shares | -68% | |
| 20Weak | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $30k 296 shares | -7% | |
| 35Weak | CORCEPT THERAPEUTICS INC | James N Wilson director | $1.1M 10,000 shares | -1% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Joseph Douglas Lyon See Remarks | $1.1M 10,000 shares | -64% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Roberto Wandenkolk Vieira President, Oncology | $6.5M 58,333 shares | -93% | |
| 40Moderate | CORCEPT THERAPEUTICS INC | Sean Maduck See Remarks | $2.9M 25,000 shares | -72% | |
| 26Weak | CORCEPT THERAPEUTICS INC | Daniel N Swisher JR director | $159k 2,200 shares | -100% | |
| 45Moderate | CORCEPT THERAPEUTICS INC | Joseph K Belanoff Chief Executive Officer | $2.8M 40,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.